Abstract
SUMMARY: Simplicity and sufficiency in the management of renal anaemia were first envisaged with the development and production of recombinant human erythropoietin (epoetin). Recent years, however, have seen the publication of several studies examining the optimal administration of epoetin, the emergence of a new erythropoietic agent (Novel Erythropoietic Stimulating Protein, NESP), recognition of the need for supraphysiological iron levels, and the possible use of many potential adjuvant agents. Together, these factors have made the management of renal anaemia substantially more complex, perhaps even to the point of confusion. the purpose of this review, therefore, is to examine the evidence relating to these factors in order to offer a summary of their known effects on anaemia management, hopefully with some progress towards the initial goals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
